You are not authorized to access this page.
  1. "Population Sciences Research Program"
Formats
  1. Journal Article (7144)
  2. Meeting Abstract (3307)
  3. Book Section (330)
  4. Review (289)
  5. Editorial (253)
  6. Research Letter (116)
  7. Correspondence (111)
  8. Conference Paper (67)
  9. Guidelines (59)
  10. Miscellaneous (41)
  11. Book Whole (24)
Groups
  1. Population Sciences Research Program (11741)
  2. Survivorship Research (5670)
  3. Department of Medicine (5135)
  4. Epidemiology and Biostatistics (4867)
  5. Solid Tumor Oncology Division (3334)
  6. Surgery (2966)

More Groups

People
  1. Andrew Vickers (880)
  2. Kenneth Offit (788)
  3. Mark Robson (676)
  4. Steven Horwitz (645)
  5. T Peter Kingham (609)
  6. Katherine Panageas (512)

More People

Years
  1. 2025 (236)
  2. 2024 (722)
  3. 2023 (821)
  4. 2022 (828)
  5. 2021 (786)
  6. 2020 (738)

More Years

Publications
  1. Journal of Clinical Oncology (1246)
  2. Blood (374)
  3. Psycho-Oncology (347)
  4. Cancer (240)
  5. Cancer Research (234)
  6. Annals of Surgical Oncology (233)

More Publications

Publishers
  1. American Society of Clinical Oncology (1412)
  2. Elsevier Inc. (1128)
  3. Springer (1112)
  4. Elsevier Science, Inc. (816)
  5. Oxford University Press (753)
  6. Wiley Blackwell (614)

More Publishers

Results (11741)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A comprehensive clinical next generation sequencing-based assay can impact hematopathologic diagnosis in a significant subset of patients with hematologic malignancies
    Meeting Abstract

    Pichardo, J. D.; Feldstein, J. T.; Arcila, M.; Batlevi, C.; Zelenetz, A. D.; Moskowitz, C. H.; Horwitz, S. M.; Tallman, M. S.; Stein, E. M.; Klimek, V. M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Prognostic importance of health-related quality of life and fatigue in newly diagnosed glioblastoma
    Meeting Abstract

    Peters, K.; Randazzo, D.; Affronti, M.; Lipp, E.; McSherry, F.; Herndon, J.; Flahiff, C.; Miller, E.; Woodring, S.; Freeman, M.; more...
    Neuro-Oncology (2014)

    Fulltext@MSK | Save
  • Dose-adjusted EPOCH plus /- rituximab in older patients with high grade diffuse large B-cell lymphoma, Burkitt and T-cell lymphoma: An effective regimen with acceptable toxicity profile
    Meeting Abstract

    Owens, C. N.; Migliacci, J. C.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; Younes, A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Duvelisib (IPI-145), a PI3K-δ,γ inhibitor, is clinically active in patients with relapsed/refractory chronic lymphocytic leukemia
    Meeting Abstract

    O'Brien, S.; Patel, M.; Kahl, B. S.; Horwitz, S. M.; Foss, F. M.; Porcu, P.; Sweeney, J.; Allen, K.; Faia, K.; Stern, H. M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Intermittent high dose (pulsatile) erlotinib for EGFRvIII mutant recurrent malignant gliomas: A pilot clinical trial
    Meeting Abstract

    Lassman, A.; Grommes, C.; Panageas, K.; Iwamoto, F.; DeAngelis, L.; Kaley, T.; Gavrilovic, I.; Pentsova, E.; Omuro, A.; Corpuz, C.; more...
    Neuro-Oncology (2014)

    Fulltext@MSK | Save
  • Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides or Sezary syndrome: Final results show significant clinical activity and suggest correlation with CD30 expression
    Meeting Abstract

    Kim, Y. H.; Tavallaee, M.; Rozati, S.; Sundram, U.; Salva, K.; Wood, G. S.; Li, S.; Krathen, M.; Nagpal, S.; Reddy, S.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Duvelisib (IPI-145), a phosphoinositide-3-kinase-δ,γ inhibitor, shows activity in patients with relapsed/refractory T-cell lymphoma
    Meeting Abstract

    Horwitz, S. M.; Porcu, P.; Flinn, I.; Kahl, B. S.; Sweeney, J.; Stern, H. M.; Douglas, M.; Allen, K.; Kelly, P.; Foss, F. M.
    Blood (2014)

    Fulltext@MSK | Save
  • Safety and early efficacy analysis of a novel combination of the PARP inhibitor veliparib (ABT-888) plus bendamustine and rituximab in patients with lymphoma
    Meeting Abstract

    Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Moskowitz, C. H.; Noy, A.; Portlock, C. S.; Palomba, M. L.; Straus, D. J.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • A phase 1 evaluation of duvelisib (IPI-145), a PI3K-δ,γ inhibitor, in patients with relapsed/refractory iNHL
    Meeting Abstract

    Flinn, I.; Oki, Y.; Patel, M.; Horwitz, S. M.; Foss, F. M.; Sweeney, J.; Allen, K.; Douglas, M.; Steelman, L.; Dunbar, J.; more...
    Blood (2014)

    Fulltext@MSK | Save